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Environmental  nanoparticles  and manufactured  nanoparticles  (MNMs)  can share  many  of  the  same
physicochemical  properties  and, therefore,  could  have  similar  toxicological  profiles.  Inhalation  of
nanoparticles  in air  pollution  has  effects  throughout  the  body;  however,  the  potential  for  inhaled  MNMs
to  affect  multiple  organs  requires  further  investigation.  The  biological  mechanisms  that  link  nanoparti-
cles  deposition  in  the  lung  to their  systemic  actions  remain  to be  established;  however,  the passage  of
nanoparticles  into  the  blood  (“translocation”)  represents  a compelling  explanation.  This  article  highlights
experimental  work  in  animals  and  man  showing  that inhaled  gold  nanoparticles  pass  into the  blood  andanomaterials
ir pollution
ranslocation
ystemic actions
ulti-organ toxicity
accumulate  at sites  of  vascular  disease.  The  article  discusses  the  properties  of  nanoparticles  that  could
influence  translocation  and  highlights  some  avenues  for future  research.  The  processes  described  have
clear relevance,  both  for  MNMs  and  sources  of  nanoparticles  in  air pollution.  The  authors  emphasise
the  need  for risk  assessment  of potential  nanoparticle  exposure  routes  that  consider  the  multiple  organ
systems.
© 2019  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY licenseOver the last few decades, there has been increasing recognition
f the shared interests of researchers that investigate the health
ffects of ultrafine particulate matter (PM) in air pollution and
he toxicological effects of engineered nanoparticles/manufactured
anomaterials (MNM)  [1]. Both types of substance have the defin-
ng property of their small size (ultrafine particles are particles
ith diameter less than 100 nm;  nanomaterials have at least one
imension smaller than 100 nm)  and both classes of particles share
ome of the physicochemical properties that are believed to be
ritical to their biological actions and toxicity [2]. However, there
re also clear parallels between the methods used to research
hese fields and the challenges that researchers face in assessing
heir potential health effects. While the health effects of partic-
late air pollution have been recognised for many decades (even
enturies), ‘nanotoxicology’ is a relatively young area of research.
owever, the rapid development of nanotechnologies for a vast
rray of applications (including human administration for medical
iagnostics and drug delivery) underscores the importance of nan-Please cite this article in press as: J.B. Raftis, M.R. Miller, Nanoparti
problem, Nano Today (2019), https://doi.org/10.1016/j.nantod.2019.0
toxicological research. While the annual number of publications
or nanotechnology now overshadows air pollution research [1],
∗ Corresponding author at: The University of Edinburgh, Centre for Cardiovascular
cience, 47 Little France Crescent, Edinburgh, EH4 3RL, United Kingdom.
E-mail address: mark.miller@ed.ac.uk (M.R. Miller).
ttps://doi.org/10.1016/j.nantod.2019.03.010
748-0132/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
the health effects of particles in air pollution are well established
by comparison.
Globally, air pollution has been estimated to be responsible for
several million premature deaths every single year [3]. While air
pollution is a complex cocktail of different chemical constituents
from many different sources, particulate matter (PM) is believed
to be the key species driving the adverse cardiovascular (which
are responsible for two-thirds of the attributable mortality [3]) [4].
These associations are more robust for PM2.5 than PM10 (PM with
diameters less than 2.5 and 10 m respectively) [5]. Ultrafine PM
(PM with a diameter less 100 nm;  “PM0.1”; i.e. nanoparticles) are
likely to have an even greater biological action on an equivalent
mass basis. Due to current limitations in measuring ultrafine PM in
the environment, studies can rarely ascribe health parameters to
ultrafine alone. Nonetheless, PM10 and PM2.5 metrics will include
a proportion of ultrafine particles (especially where combustion
sources are present), and these particles can be present in large
numbers with a large reactive surface area, even where the contri-
bution to mass metrics is low. As we will discuss, the nanosize of
ultrafine PM also brings with it the possibility of additional means
by which these particles can affect health.
The pulmonary effects of PM exposure are well established, andcle translocation and multi-organ toxicity: A particularly small
3.010
the last two decades have cemented the cardiovascular system as
an organ system that is acutely vulnerable to PM in air pollution.
Controlled exposure studies to pollutants such as diesel exhaust
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ARTICLE IN PRESSG ModelNANTOD-741; No. of Pages 5
2 J.B. Raftis, M.R. Miller / Nano Today xxx (2019) xxx–xxx
ange 
(
a
i
w
t
b
c
[
s
a
[
d
(
p
i
t
a
l
o
e
a
o
l
o
o
c
s
t
i
a
fi
e
l
g
t
t
t
oFig. 1. Particulate air pollution has been linked to a wide r
that is rich in ultrafine particles) can induce lung inflammation [6]
nd impairment of cardiovascular parameters [4,7]. However, there
s now a burgeoning list of other extrapulmonary effects associated
ith exposure to air pollution (albeit PM10, PM2.5, or proximity
o roadways, rather than ultrafine PM per se).  These include dia-
etes and metabolic syndrome [8], neurological effects (impaired
ognition, depression, Alzheimer’s disease and Parkinson’s disease
9,10]) and potential teratogenic and epigenetic effects from expo-
ure in utero [11,12]. There are also emerging reports of air pollution
ffecting the kidneys [13], the gastrointestinal system [14], the liver
15], stem cells [16], mortality following organ transplantation [17],
iseases of the skin [18], fertility [19] and various cancers [20–23]
Fig. 1).
The biological mechanisms that account for the extra-
ulmonary effects of inhaled PM remain unknown. Of particular
nterest are the mechanisms by which effects on the lung progress
o other organs. Identifying these pathways is fundamental for
ir pollution research and nanotoxicology. Inhalation remains a
ikely route of accidental exposure to nanomaterials (e.g. in an
ccupational or environmental setting), yet investigations into
xtrapulmonary effects tend to focus on basic blood biochemistry
nd gross pathology, rather than physiological function in specific
rgan systems. Three central pathways linking exposure in the
ung to effects on distant organs have been theorised: 1) induction
f lung inflammation that signals to the circulation 2) activation
f alveolar sensory receptors leading to alterations in neurologi-
al function and changes in endocrine release, and 3) passage of
maller nanoparticles into the circulation (“translocation”) where
hey directly harm organs [24].
There is now a consistent body of evidence from animal stud-
es which demonstrate nanoparticles can cross the alveolar barrier
nd settle in extrapulmonary organs. Until recently, empirical con-
rmation of a similar process in humans has been lacking. Nemmar
t al. showed the passage of technetium particles into the blood fol-
owing inhalation in healthy volunteers [25]. However, subsequent
roups failed to reproduce these experiments [26] and suggestedPlease cite this article in press as: J.B. Raftis, M.R. Miller, Nanoparti
problem, Nano Today (2019), https://doi.org/10.1016/j.nantod.2019.0
hat leaching of the radiolabel from the particle could account for
he earlier findings. In 2017, through a collaboration with scien-
ists in the Netherlands, our group demonstrated translocation
f inhaled gold nanoparticles using human subjects [27] (Fig. 2).of conditions affecting many different organs of the body.
We  used high-resolution (limit of quantification: 0.03 ng gold/g of
blood) inductively coupled plasma mass spectrometry to detect
total gold in blood and urine of healthy volunteers following a 2-h
inhalation of 5 nm gold nanoparticles (primary size). Surprisingly
gold was still present in blood and urine of the volunteers three
months after exposure, at levels higher than the initial 24-h period,
pointing towards systemic retention and delayed urinary excretion.
These observations align with a recent study in rats using 20 nm
radiolabelled gold, showing that initial urinary clearance is slow
and that blood levels of gold were higher at 28 days after exposure
compared to earlier time-points [28]. We  went on to demonstrate
that translocation was size-dependent, with greater translocation
of smaller nanoparticles into the blood (<30 nm) and urine (<10 nm)
(primary particle sizes).
Despite using a relatively high dose of gold (∼0.4 mg total
inhaled dose) and a very high sensitivity detection method, the level
of gold in blood was close to the limit of detection (0.03 ng/g) at time
points <24-h from the end of the exposure [29]. The question then
remains, is the translocation of these low amounts of nanoparticles
physiologically relevant? This is a challenging question to answer.
We chose gold nanoparticles for a variety of practical reasons, the
most important being that they would not cause harm to the volun-
teers and could be reliably detected. Controlled exposures of dilute
diesel exhaust (a pollutant rich in combustion-derived nanopar-
ticles) caused marked cardiovascular actions in human subjects,
including impairment of blood vessel relaxation, promotion of
thrombosis and increased the susceptibility of the heart to ischemia
[4]. These alterations were shown to be driven by the particulate
component of diesel exhaust [30,31], although these investigations
were not able to address specifically if particle translocation to the
cardiovascular system accounted for these effects.
To address this matter, we  investigated the possible fate of
translocated nanoparticles once in the blood [27]. While the mass
dose of translocated particles in the blood is low, particle num-
bers could be sufficient to cause disproportional biological effects
if they reached areas of the body that are especially susceptible tocle translocation and multi-organ toxicity: A particularly small
3.010
their effects. Using an animal model of atherosclerosis (a disease
characterised by the build-up of fats and lipids in the arteries than
can occlude blood flow) we  demonstrated that 5 nm gold nanopar-
ticles instilled to the lung could be detected in vascular tissue 24-h
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Fig. 2. Translocation of inhaled gold nanoparticles in mice and human subjects (data from Miller & Raftis et al. 2017) [26] A. (i) Inhalation of gold nanoparticles (5 nm primary
particle  size) in healthy volunteers during moderate exercise; (ii) Study protocol; (iii) Detection of gold in blood and urine by high-resolution inductively coupled plasma
mass  spectrometry, following 2-h inhalation of gold nanoparticles (thin horizontal dotted lines represent limit of quantification (LOQ), grey symbols are below LOQ but
above  limit of detection). B. Small nanoparticles translocated more readily than large particles in (i) healthy human volunteers (following inhalation of primary particle sizes:
∼ cumu
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g5  nm and ∼30 nm)  and (ii) mice (∼24-h following instillation of suspensions). C. Ac
ccumulation in heavily diseased arteries of apolipoprotein-E knockout mice; (ii) 
rteries  of patients with a history of stroke, following inhalation of gold nanopartic
ater. Importantly, the accumulation of gold was greater in diseased
rteries compared with disease-free vessels. As a final study, we
emonstrated that inhaled gold nanoparticles could be detected
n atherosclerotic lesions of the carotid arteries in human subjects
ith a history of ischemic stroke.
These results ‘add another piece to the jigsaw’ as to how
nhaled nanoparticles mediate their systemic effects. The findings
re intriguing and raise many questions. From a practical perspec-
ive, we now need to confirm if these observations hold for particles
ther than gold, in particular to environmental nanoparticles such
s diesel exhaust particles (DEP). Combustion-derived nanoparti-
les have a vast array of harmful chemical species on their surface,
hich contribute to its oxidative capacity, and pro-inflammatory
otential [24]. These properties make it highly likely that if DEP
eaches inflamed tissues in the same way as gold nanoparticles
o, it will be more likely to promote disease (especially so with
umulative exposure over a lifetime) and potentiate rupture of
therosclerotic plaques (the trigger that instigates events such as
 heart attack or stroke). Whether or not engineered nanoparticles
ould promote disease, in the same way, is far from clear. How-
ver, free radical generation, induction of cellular oxidative stress
nd pro-inflammatory responses are hallmarks of nanotoxicity [2].
herefore, many would state there is a reasonable case for limit-
ng exposure to nanomaterials with similarly low size ranges untilPlease cite this article in press as: J.B. Raftis, M.R. Miller, Nanoparti
problem, Nano Today (2019), https://doi.org/10.1016/j.nantod.2019.0
hese concerns are addressed.
A limitation of our study is that we did not address what bio-
ogical and particle characteristics determine translocation. Other
roups have shown in animal models that both particle size (and,lation of nanoparticles in atherosclerotic blood vessels; (i) Preferential nanoparticle
 Raman confocal microscopy to detect gold in the plaques taken from the carotid
 preceding day.
by the same token, surface area) and charge are important deter-
minants to translocation [32–34]. Interestingly, the coating on the
surface of the particle from either particle opsonisation [35] or
intentional surface modification [36] also affects translocation pro-
cesses, while the age of the (healthy) animal does not [28]. These
particle properties (and others) may  also affect the time-course of
translocation and clearance mechanisms [37,38]. The inflamma-
tory status of the lung may  also play a role in translocation through
changes in alveolar permeability. Research suggests that certain
sub-populations (e.g. the young, elderly or those with pre-existing
disease) could be more susceptible to the adverse effects of air pol-
lution [39]; is the same true for manufactured nanomaterials and
could this influence the potential applications for these materials?
Translocation of nanoparticles has far-reaching implications for
the fields of air pollution research and nanotoxicology. While our
focus has been chiefly from a cardiovascular perspective, translo-
cation potentially explains how inhaled particles mediate effects
throughout the body. It raises concerns that other nanoparticles
could have similar insidious effects. If translocated nanoparti-
cles selectively localise in areas of inflammation, then what are
the implications for other inflammatory conditions or chronic
inflammation associated with various cancers? If nanoparticles
can cross the alveolar barrier, what other barriers can they cross?
The blood-brain-barrier, or the placenta? Indeed, the brain andcle translocation and multi-organ toxicity: A particularly small
3.010
maternal-foetal effects are hot topics in air pollution research
[40,41], and of interest (or concern) for nanomedicine e.g. for
imaging, drug delivery or as a therapeutic agent? [42–44]. If
nanoparticles can cross these barriers in significant numbers, then
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hat are the dose implications for nanomaterials designed for
njection directly into the bloodstream? Could manufactured nano-
aterials act as carriers for other chemicals in a manner analogous
o diesel exhaust particles carrying chemicals from incomplete
ombustion on their surface? While we are at risk of descend-
ng into a Cassandra complex, there is little doubt that the fate
f nanoparticles in the body is paramount to understanding their
ealth risks. A better understanding of how nanoparticles cross
etween organs will greater assist the development of new ther-
gnostic agents. With the accumulated knowledge from both air
ollution research and nanotoxicology, there is the potential to pre-
ict and avoid any probable toxicity of nanomaterials; ultimately
llowing us to harness their unique properties safely, to enhance
ur lives.
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